argenx NV ADR (ARGX)vsIncyte Corporation (INCY)
ARGX
argenx NV ADR
$697.05
+2.89%
HEALTHCARE · Cap: $42.05B
INCY
Incyte Corporation
$92.23
+1.78%
HEALTHCARE · Cap: $18.03B
Smart Verdict
WallStSmart Research — data-driven comparison
Incyte Corporation generates 21% more annual revenue ($5.14B vs $4.24B). ARGX leads profitability with a 30.5% profit margin vs 25.0%. INCY appears more attractively valued with a PEG of 0.32. INCY earns a higher WallStSmart Score of 83/100 (A-).
ARGX
Buy63
out of 100
Grade: C+
INCY
Exceptional Buy83
out of 100
Grade: A-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-526.8%
Fair Value
$133.14
Current Price
$697.05
$563.91 premium
Margin of Safety
+67.0%
Fair Value
$299.99
Current Price
$92.23
$207.76 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Revenue surging 73.0% year-over-year
Every $100 of equity generates 20 in profit
Growing faster than its price suggests
Strong operational efficiency at 27.4%
Growing faster than its price suggests
Safe zone — low bankruptcy risk
Every $100 of equity generates 30 in profit
Keeps 25 of every $100 in revenue as profit
Attractively priced relative to earnings
Strong operational efficiency at 25.6%
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Earnings declined 31.9%
No major concerns identified
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Revenue Growth, Return on Equity. Profitability is solid with margins at 30.5% and operating margin at 27.4%. Revenue growth of 73.0% demonstrates continued momentum.
Bull Case : INCY
The strongest argument for INCY centers on PEG Ratio, Altman Z-Score, Return on Equity. Profitability is solid with margins at 25.0% and operating margin at 25.6%. Revenue growth of 27.8% demonstrates continued momentum.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, EPS Growth.
Bear Case : INCY
No major red flags identified for INCY, but monitor valuation.
Key Dynamics to Monitor
INCY carries more volatility with a beta of 0.84 — expect wider price swings.
ARGX is growing revenue faster at 73.0% — sustainability is the question.
INCY generates stronger free cash flow (521M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
INCY scores higher overall (83/100 vs 63/100), backed by strong 25.0% margins and 27.8% revenue growth. Both earn "Exceptional Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Incyte Corporation
HEALTHCARE · BIOTECHNOLOGY · USA
Incyte Corp is an American pharmaceutical company based in Alapocas, Delaware.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?